Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI
A Proof of Concept Study to Evaluate the Safety and Efficacy of Voxzogo (Vosoritide) for the Treatment of Growth Deficits in MPS IVA and VI
Sponsor: University of California, San Francisco
This PHASE1/PHASE2 trial investigates MPS IVA and MPS VI and is currently ongoing. University of California, San Francisco leads this study, which shows 9 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Nov 2024 — Mar 2026 [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 4 earlier versions
-
Oct 2023 — Dec 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jul 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .